| CLINICAL STUDY |
These results were sufficiently encouraging to merit investigation of the effects of AG7088 in naturally acquired rhinovirus infections. A large-scale multicentre trial at more than 50 sites in the US has been initiated. In this double-blind, placebo-controlled, clinical trial intranasal doses of AG7088 are being administered to cold sufferers within 36 hours of cold symptoms first appearing. This trial will be important in determining whether AG7088 can work rapidly enough following the onset of cold symptoms to meet primary endpoints.
|